OrbiMed Capital GP V LLC is Director & 10% Owner at Corvus Pharmaceuticals, Inc. (CRVS). They have made 15 open-market trades across 8 companies since 2014, most recently 2025-10-23.
CIK 0001615374
5 open-market purchases totalling $4.8M since 2014, against 10 sales. Across 5 scored buys the stock is up 17.7% at ninety days, and 14.9 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 80% | 80% | 80% |
| Avg Move | +11.1% | +13.7% | +17.7% |
| Alpha | +13.1% | +11.5% | +14.9% |
| Scored | 5 | 5 | 5 |
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 70% | 60% | 50% |
| Avg Move | -13.9% | -9.3% | -1.9% |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PMVP | SELL | 2025-10-23 | 2025-10-27 | $1.52 | $1.5M | -18.3% | -12.4% | -23.5% |
| PMVP | SELL | 2022-05-26 | 2022-05-31 | $15.93 | $836K | -18.6% | +20.3% | +12.4% |
| CMPX | BUY | 2022-05-06 | 2022-05-10 | $1.57 | $197K | +48.0% | +44.0% | +48.6% |
| CRVS | SELL | 2021-09-20 | 2021-09-22 | $6.09 | $6.8M | -33.4% | -38.0% | -63.0% |
| ARPO | SELL | 2020-12-08 | 2020-12-10 | $1.96 | $42K | -53.2% | -46.4% | -27.7% |
| INSP | SELL | 2020-08-18 | 2020-08-19 | $108.54 | $4.7M | +8.6% | +15.3% | +54.5% |
| INSP | SELL | 2020-03-03 | 2020-03-05 | $84.25 | $42.1M | -39.3% | -34.1% | +3.9% |
| CRVS | BUY | 2019-08-06 | 2019-08-08 | $3.51 | $501K | +9.1% | +3.2% | +1.9% |
| INSP | SELL | 2018-12-11 | 2018-12-13 | $37.60 | $23.1M | -0.6% | +17.3% | +36.3% |
| ADAP | SELL | 2018-06-06 | 2018-06-06 | $13.49 | $22K | -4.3% | -11.3% | -15.4% |
| RYTM | SELL | 2018-05-22 | 2018-05-24 | $30.40 | $1.1M | +15.6% | +10.8% | +4.2% |
| RYTM | SELL | 2018-05-18 | 2018-05-21 | $30.84 | $6.2M | +4.8% | -14.5% | -0.2% |
| CRVS | BUY | 2016-06-21 | 2016-06-21 | $12.87 | $336K | +9.3% | +7.1% | +11.8% |
| CRVS | BUY | 2016-06-14 | 2016-06-16 | $12.49 | $187K | +12.4% | +15.7% | +27.5% |
| LOXO | BUY | 2014-08-06 | 2014-08-06 | $13.00 | $3.6M | -23.5% | -1.3% | -1.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| ARPO | 21,400 | $706K |
| ADAP | 4,901,310 | $269K |
| Total | $495.5M |
Shares reported on the most recent Form 4, priced at the 2025-10-27 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Scored | 10 | 10 | 10 |